Comparative effectiveness of Lopinavir/Ritonavir‐based regimens in COVID‐19
| Autor: | Ge-Fei He, Qiang Qu, Guo-Hua Li, Xiang-Yu Chen, Qiong Lu, Ying Chen, Juan-Juan Huang, Jiao-Jiao Wang, Jian Qu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Coronavirus disease 2019 (COVID-19) Physiology Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lopinavir/ritonavir Pharmacology Lopinavir Virus 03 medical and health sciences 0302 clinical medicine Interferon Physiology (medical) medicine Humans Drug Interactions Epidemic disease Retrospective Studies Ritonavir business.industry Middle Aged COVID-19 Drug Treatment Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Female business medicine.drug |
| Zdroj: | Clinical and Experimental Pharmacology and Physiology |
| ISSN: | 1440-1681 0305-1870 |
| DOI: | 10.1111/1440-1681.13425 |
| Popis: | The coronavirus disease 2019 (COVID-19) is an epidemic disease caused by the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and spreading throughout the world rapidly. Here we evaluated the efficacy of the Lopinavir/Ritonavir (LPV/r) and its combination with other drugs in the treatment of COVID-19. We included 170 confirmed COVID-19 patients who had been cured and discharged. Their antiviral therapies were LPV/r alone or combinations with interferon (IFN), Novaferon and Arbidol. We evaluated the medication efficacy by comparing the time of the negative nucleic acid conversion and the length of hospitalization mainly. The LPV/r + Novaferon [6.00 (4.00-8.00) and 7.50 (5.00-10.00) days] had shorter time of the negative nucleic acid conversion (P = .0036) and shorter time of hospitalization (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |